Skip to main content

Table 1 Pooled analysis of efficacy of PD1/PD-L1 antagonist in soft-tissue sarcomas

From: PD1/PD-L1 targeting in advanced soft-tissue sarcomas: a pooled analysis of phase II trials

All population (n = 384)

  

ORR

NPR

  

15.1

58.5

  

95% CI 8.6% ; 25.1%

 

95% CI 44.4% ; 71.3%

 

Efficacy by histological subtype

Histological subtype

N patients

ORR

 

NPR

 

%

95% CI

%

95% CI

 UPS

103

15.7

7.5-30.0

50.5

39.0-61.9

 LMS

82

6.9

2.0-21.3

54.1

29.3-77.0

 DDLPS

61

7.3

1.2-33.7

54.5

24.5-81.6

 ASPS

41

48.8

26.0-72.0

80.5

54.1-93.5

 Others

97

10.3

5.0-20.2

52.1

35.5-68.3

Efficacy by the therapeutic strategy

 PD1/PD-L1 single agent

153

18.7

2.1-71.6

63.6

25.3-90.0

 Combination with other immunotherapy

114

11.4

3.5-31.4

57.9

18.2-89.4

 Combination with non-immunological agent

117

14.0

0.5-84.2

53.8

7.9-94.0

  1. ASPS alveolar soft part sarcoma, DDLPS liposarcoma, LMS leiomyosarcoma, ORR objective response rate, NPR non-progression rate, UPS undifferentiated pleomorphic sarcoma